Targeting a pre-mRNA structure with bipartite antisense molecules modulates tau alternative splicing

scientific article

Targeting a pre-mRNA structure with bipartite antisense molecules modulates tau alternative splicing is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1093/NAR/GKS710
P932PMC publication ID3479178
P698PubMed publication ID22844088
P5875ResearchGate publication ID230586419

P2093author name stringYang Liu
Michael S Wolfe
Lilia Rodriguez
Eleanor Peacey
P2860cites work5' splice site mutations in tau associated with the inherited dementia FTDP-17 affect a stem-loop structure that regulates alternative splicing of exon 10.Q52535062
A phosphorothioate oligonucleotide blocks reverse transcription via an antisense mechanismQ71614263
Role of RNA structure in regulating pre-mRNA splicingQ24631714
Enhanced RNA cleavage within bulge-loops by an artificial ribonucleaseQ24793857
Variation in alternative splicing across human tissuesQ24809417
Progress toward therapy with antisense-mediated splicing modulationQ27489807
Structure of tau exon 10 splicing regulatory element RNA and destabilization by mutations of frontotemporal dementia and parkinsonism linked to chromosome 17Q27618950
Structural Basis for Stabilization of the Tau Pre-mRNA Splicing Regulatory Element by Novantrone (Mitoxantrone)Q27655658
Alternative isoform regulation in human tissue transcriptomesQ27861118
Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17Q28274687
Tau-mediated neurodegeneration in Alzheimer's disease and related disordersQ29618148
The mutational spectrum of single base-pair substitutions in mRNA splice junctions of human genes: causes and consequencesQ29619441
Eukaryotic gene transcription with purified componentsQ29620213
Aberrant splicing of tau pre-mRNA caused by intronic mutations associated with the inherited dementia frontotemporal dementia with parkinsonism linked to chromosome 17.Q33963856
RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platformQ34020786
Splicing of a critical exon of human Survival Motor Neuron is regulated by a unique silencer element located in the last intronQ34353625
RNA structure and the mechanisms of alternative splicing.Q35146258
A G-rich element forms a G-quadruplex and regulates BACE1 mRNA alternative splicingQ35928555
Mutation in the tau gene in familial multiple system tauopathy with presenile dementiaQ36507684
Mechanisms of the inhibition of reverse transcription by antisense oligonucleotidesQ36798960
Delivery of bifunctional RNAs that target an intronic repressor and increase SMN levels in an animal model of spinal muscular atrophyQ37154271
Tau mutations in neurodegenerative diseasesQ37307240
Correction of alternative splicing of tau in frontotemporal dementia and parkinsonism linked to chromosome 17.Q38296901
Effects of RNA secondary structure on cellular antisense activityQ38315200
Mechanisms of the inhibition of reverse transcription by unmodified and modified antisense oligonucleotidesQ38316118
Selective inhibition of cell-free translation by oligonucleotides targeted to a mRNA hairpin structure.Q38336876
Stabilization of the tau exon 10 stem loop alters pre-mRNA splicingQ39958205
Antisense 2'-O-alkyl oligoribonucleotides are efficient inhibitors of reverse transcriptionQ40392535
Mitoxantrone analogues as ligands for a stem-loop structure of tau pre-mRNA.Q41808723
P275copyright licenseCreative Commons Attribution-NonCommercial 3.0 UnportedQ18810331
P6216copyright statuscopyrightedQ50423863
P433issue19
P407language of work or nameEnglishQ1860
P921main subjectalternative mRNA splicing, via spliceosomeQ21114084
P304page(s)9836-9849
P577publication date2012-07-25
P1433published inNucleic Acids ResearchQ135122
P1476titleTargeting a pre-mRNA structure with bipartite antisense molecules modulates tau alternative splicing
P478volume40

Reverse relations

cites work (P2860)
Q30867681Ametantrone-based compounds as potential regulators of Tau pre-mRNA alternative splicing
Q27007056Antisense oligonucleotides: treating neurodegeneration at the level of RNA
Q38184276Antisense-mediated exon skipping: taking advantage of a trick from Mother Nature to treat rare genetic diseases
Q38211673Development of therapeutic splice-switching oligonucleotides.
Q45870549Emerging Diagnostic and Therapeutic Strategies for Tauopathies
Q38186137Exon-skipping antisense oligonucleotides to correct missplicing in neurogenetic diseases
Q41705374HIV-1 splicing at the major splice donor site is restricted by RNA structure
Q33786251Identification of a Peptide for Systemic Brain Delivery of a Morpholino Oligonucleotide in Mouse Models of Spinal Muscular Atrophy
Q38263698Invited review: Drug development for tauopathies
Q90743959Nuclear and Cytoplasmatic Quantification of Unconjugated, Label-Free Locked Nucleic Acid Oligonucleotides
Q50130748Nucleic Acid-Based Theranostics for Tackling Alzheimer's Disease
Q92753261RNA Secondary Structure-Based Design of Antisense Peptide Nucleic Acids for Modulating Disease-Associated Aberrant Tau Pre-mRNA Alternative Splicing
Q93355206RNA Splicing and Disease: Animal Models to Therapies
Q38242065RNA triplexes: from structural principles to biological and biotech applications
Q47655684Sequence-specific and Selective Recognition of Double-stranded RNAs over Single-stranded RNAs by Chemically Modified Peptide Nucleic Acids
Q37211004Splice-switching antisense oligonucleotides as therapeutic drugs
Q36780738Targeting RNA splicing for disease therapy
Q27687153Targeting mRNA for Alzheimer's and related dementias.
Q33835923Template-directed synthesis of a small molecule-antisense conjugate targeting an mRNA structure
Q28119005The Role of MAPT in Neurodegenerative Diseases: Genetics, Mechanisms and Therapy
Q27005032The role of tau in neurodegenerative diseases and its potential as a therapeutic target
Q39185494Trans-splicing correction of tau isoform imbalance in a mouse model of tau mis-splicing

Search more.